AVITA Medical, Inc. (AVH.AX) Stock Analysis

AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

Tue, August 25, 2026 at 5:07 PM UTC 2 min read

AVITA Medical (AVH.AX) saw an increase in its stock fair value following positive data from its PermeaDerm product, which is designed for wound care. Analysts have raised their price targets for the stock, reflecting growing confidence in the company's potential for future growth. This development is significant for investors as it suggests a strengthening market position and potential for higher returns.

Read full article →

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, August 18, 2026 at 11:45 AM UTC 3 min read

AVITA Medical (AVH.AX) announced positive results from its PermeaDerm® study, showing a 70% economic advantage over traditional allograft treatments while achieving comparable clinical outcomes. This development is significant for investors as it highlights the cost-effectiveness and potential market competitiveness of PermeaDerm®, which could lead to increased adoption in clinical settings and drive revenue growth for the company.

Read full article →